Intratumoral plasma cells: More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?
- PMID: 35216677
- DOI: 10.1016/j.ccell.2022.02.008
Intratumoral plasma cells: More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?
Abstract
In this issue of Cancer Cell, Patil et al. report that increased plasma cell signatures are predictive of an extended overall survival in non-small-cell lung cancer patients treated with a PD-L1 inhibitor and that these cells are associated with the presence of tertiary lymphoid structures.
Copyright © 2022. Published by Elsevier Inc.
Conflict of interest statement
Declaration of interests M.-C.D.-N. is inventor on four patent applications (WO 2013/107907, WO 2015/007625, WO 2017/032867, and EP21305176.6) in the field of tumor-associated TLS. J.-L.T. declares no competing interests.
Comment on
-
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.Cancer Cell. 2022 Mar 14;40(3):289-300.e4. doi: 10.1016/j.ccell.2022.02.002. Epub 2022 Feb 24. Cancer Cell. 2022. PMID: 35216676
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials